Workflow
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?

Company Overview - 4D Molecular Therapeutics has made significant progress in its drug pipeline, with the FDA clearing its investigational new drug application for 4D-175, a genetic medicine for geographic atrophy [1] - The company also presented positive data for its lead candidate, 4D-150, targeting wet age-related macular degeneration [1] Stock Performance - 4D Molecular Therapeutics' shares increased by 11.1% in the last trading session, closing at $25.79, with trading volume significantly higher than usual [4] - This rise contrasts with a 3.6% loss over the previous four weeks [4] Financial Expectations - The company is projected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of +6.5% [5] - Expected revenues for the upcoming report are $1.9 million, which represents a substantial increase of 691.7% from the same quarter last year [5] Earnings Estimates - The consensus EPS estimate for 4D Molecular Therapeutics has remained unchanged over the last 30 days, indicating stability in earnings expectations [6] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, suggesting the need for monitoring future performance [6] Industry Context - 4D Molecular Therapeutics is part of the Zacks Medical - Drugs industry, which includes other companies like Journey Medical Corporation [3] - Journey Medical's stock has experienced a decline of 7.2% over the past month, while 4D Molecular Therapeutics has shown a more favorable performance [3] Zacks Rank - 4D Molecular Therapeutics currently holds a Zacks Rank of 2 (Buy), indicating positive market sentiment [8]